Google
CVM — CEL-SCI CORP (Healthcare >> Biotechnology)
CVM FAQ
What is CVM's ROE?
CEL-SCI CORP reports a Return on Equity (ROE) of -330.21%.
What is CVM's dividend yield?
CEL-SCI CORP offers a dividend yield of 0.00%.
What is CVM's Deepscope Quality Score?
Deepscope rates CVM's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CVM?
Deepscope's AI Timing Score for CVM is 28 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CVM belong to?
CEL-SCI CORP is classified under the Healthcare >> Biotechnology sector on the NYSE MKT exchange.
|
USD 1.37
Price
-0.16
(-10.46%)
Day Change
|
|
|---|
CVM, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 77 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.37 |
| PBV / Sector |
3.23 / 4.63
|
| Earning Per Share | -1.40 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
1.02 M
GREAT
|
| Average 1W Daily Value |
0.30 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
50% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:23 |
| Symbol | CVM |
| Name | CEL-SCI CORP |
| Sector | Healthcare >> Biotechnology |
| Market | NYSE MKT |
| Listed Shares | 14.49 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 22.17 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 8229 Boone Boulevard, Vienna, VA, United States, 22182
Phone: 703 506 9460
Website: https://cel-sci.com
Sector: Healthcare >> Biotechnology
Description: CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
